NEWSROOM

Healthcare

PRISM MarketView – Biotech Breakfast

PRISM MarketView – Biotech Breakfast

Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 - PRISM MarketView - Healthcare equities finished lower on Friday, in line with broad declines across the market. The S&P 500 Healthcare Index closed down (1.52%) versus the S&P 500 Index which lost (1.46%) and the XBI settled down (3.43%). The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee concluded...

read more
American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

SAN FRANCISCO, CA, April 12, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announces the sudden passing of its Chief Executive Officer, Peter Gaccione. Ray Stachowiak, Executive Chairman of American Shared Hospital Services, said, “On behalf of my colleagues at AMS, we are deeply saddened by the unexpected passing of...

read more
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 12, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectively...

read more
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant...

read more
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

-     Bio-Rad expects to make equity investment in support of deal -     Agreement provides for global exclusivity in transplant monitoring commercialization -     Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the...

read more
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

First-ever telesurgery using SSi Mantra performed on an animal in India FORT LAUDERDALE, FL, April 10, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that its SSi Mantra Surgical Robotic System has successfully completed its first-ever telesurgery procedures on an animal in India....

read more
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 

Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 09, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...

read more
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel...

read more
PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

New York, N.Y., April 05, 2024 - PRISM MarketView announces the release of an informative interview with Auto Parts 4 Less CEO Christopher Davenport, explaining the company’s strategic business model and focus on expanding its automotive eCommerce marketplace. Christopher Davenport - CEO of Auto Parts 4 Less Auto Parts 4 Less is an innovator focused on developing a world-class eCommerce marketplace for automotive parts that utilizes integrated technologies to optimize the listing, selling, and...

read more
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Pittsburgh, PA, April 03, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...

read more
American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

- Acquisition of 3 Rhode Island Radiation Therapy Cancer Centers progressing toward closing- - International Cancer Center equipment upgrade completed in Ecuador, Opening new Puebla, Mexico Center in Q2- - Lease extensions signed at 4 of 10 Gamma Knife customer sites – -Sales Pipeline continues to advance- -Conference Call Thursday, March 28th at 12:00 pm ET / 9:00 am PT - SAN FRANCISCO, CA, March 27, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company") a leading...

read more
American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

American Shared Hospital Services Pays Tribute to Ernest A. Bates, M.D., Founder and Former Chairman and CEO

Dr. Bates, Pioneering Neurosurgeon and Philanthropist, passed on March 19, 2024 SAN FRANCISCO, CA, March 26, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that Company Founder, former Chairman and Chief Executive Officer, and Board Director, Ernest A. Bates, M.D, passed away on Tuesday, March 19th at the age of...

read more
PRISM MarketView – Biotech Breakfast

PRISM MARKETVIEW PREVIEWS ANTICIPATED FDA DRUG APPROVALS FOR 2024

New York, N.Y., March 25, 2024 - PRISM MarketView - Drug development is an arduous, costly and time-consuming process for the teams involved behind the scenes, and the patients anxiously awaiting breakthroughs in different disease areas. It takes 12 years on average for a company to take a drug from discovery to commercialization, and every hard-won FDA approval is a cause for celebration for researchers, companies and the end-users whose lives may be changed by these treatments. The past few...

read more
American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call

American Shared Hospital Services Announces Fourth Quarter 2023 Earnings Conference Call

Conference Call on Thursday, March 28th at 12:00 pm ET / 9:00 am PT SAN FRANCISCO, CA, March 22, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its fourth quarter 2023 financial results on Thursday, March 28th at 12:00 pm ET / 9:00 am PT. The fourth quarter...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

BioStem Technologies to Report Fourth Quarter 2023 Financial Results on Monday, April 01, 2024

Conference Call on Monday, April 1st, at 4:30 pm ET POMPANO BEACH, FLORIDA, March 21, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced today that it plans to release its fourth quarter 2023 financial results post-market Monday, April 01, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Monday, April 01, 2024....

read more
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approval

New York, N.Y., March 18, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights the FDA’s landmark approval of Rezdiffra™ and the companies leading the charge in developing new, safe, and effective treatments for liver disease. The landmark decision has shone a light on metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic fatty liver disease, a leading cause of liver-related mortality that affects between...

read more
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

SS Innovations’ SSi Mantra Surgical Robotic System used to perform Mitral Valve Replacement

The first Mitral Valve Replacement using the Made in India SSi Mantra Surgical Robotic System was successfully performed at the Narayana Institute of Cardiac Sciences in Bengaluru, India FORT LAUDERDALE, FL, March 12, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that surgeons...

read more
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

New York, N.Y., March 07, 2024 - PRISM MarketView announces the release of an insightful interview with Lipella Pharmaceuticals’ CEO, Dr. Jonathan Kaufman, discussing the company's recent regulatory accomplishments and how investors stand to benefit. Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease (GvHD) and previously received Orphan Drug Designation for LP-10 in 2023. With these nods from the...

read more
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Clinical testing of LP-410 expected to commence in Q2 2024 Pittsburgh, PA, March 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GVHD). Lipella’s...

read more
PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

New York, N.Y., February 29, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million Americans. All areas of medicine, and all organs and body systems, are impacted by rare diseases, including rare neurological and neuromuscular diseases, metabolic, skin and bone diseases, and chromosomal disorders. Approximately 95% of rare...

read more
PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

New York, N.Y. February 26, 2024 - PRISM MarketView announces the release of an insightful interview with BioStem Technologies' (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions. BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care. The company stands out for its...

read more
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Chief Medical Officer Dr. Michael Chancellor will discuss hemorrhagic cystitis and the company’s lead candidate, LP-10 Pittsburgh, PA, February 20, 2023 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company") a pioneering, clinical-stage pharmaceutical company, announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET....

read more
PRISM MarketView Marks World Cancer Day

PRISM MarketView Marks World Cancer Day

New York, N.Y., February 01, 2024 - PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors. It is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, and is the second leading cause of death in the United States. To mark World Cancer Day, which will be held on February 4, PRISM MarketView...

read more
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

SS Innovations Demonstrates Groundbreaking Telesurgery Platform at Company’s First Multi-Specialty Robotic Surgical Conference    

Remote coronary artery suturing performed on animal model via SS Innovations’ telesurgery platform SMRSC 2024 welcomed global medical experts and innovators to explore the future of robotic surgery FORT LAUDERDALE, FL, February 01, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII) ), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, conducted a groundbreaking live...

read more
BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Amniowrap2™ Product Launch Leads Year of Highlights for BioStem Technologies

BioStem provides a business update and highlights recent accomplishments Preliminary fourth quarter net revenues of $11.5 million and full year 2023 net revenues of $16.7 million National Pricing for Amniowrap2™ effective January 1st in all 50 states and territories POMPANO BEACH, FLORIDA, January 30, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived allografts for advanced...

read more
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

SS Innovations Announces Filing of Pre-Submission Application to the Center for Devices and Radiological Health (CDRH) of the United States Food and Drug Administration

FORT LAUDERDALE, FL, January 26, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has filed a pre-submission application with the U.S. Food and Drug Administration (FDA) requesting feedback on its SSi MantraTM Surgical Robotic System. SS Innovations received acknowledgement of this pre...

read more
SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

SS Innovations Partners with India’s Leading Medical Equipment Supplier, Medikabazaar

Collaboration to facilitate sales of the SSi Mantra Surgical Robotic System to hospitals and medical facilities across India FORT LAUDERDALE, FL, January 25, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced it has entered into a partnership with India’s leading medical equipment supplier,...

read more
Remsleep Holdings Inc.’s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)

Remsleep Holdings Inc.’s DeltaWave Mask has received questions from FDA regarding 510k submission (K233415)

Tampa, FL, January 22, 2024 - RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) has received a response to the company’s 510(K) submission K233415. The agency has determined that additional information is required. The agency has asked for additional information regarding Administrative Information, Device Description, Substantial Equivalence (SE), Labeling, Biocompatibility, and...

read more

Categories

Loading
Translate »